Three-dimensional quantitation of pediatric tumor bulk
- 42 Downloads
In pediatric oncology, therapeutic decisions are made based on tumor response to chemotherapeutic agents. Sequential measurement of tumor bulk and its percent change on therapy must be accurately assessed. Will 3-dimensional (3-D) volumetric determination improve our ability to assess tumor response to therapy? Forty-five CT scans of pediatric patients with unresectable thoracic or abdominal neoplasia were assessed for tumor bulk by the standard “2-dimensional (2-D)” volume formula (cross-sectional areaxlength) and by 3-D volumetric analysis. Thirty-two examinations were performed in follow-up, and percent change in tumor size was calculated. The 2-D volume calculation overestimated tumor volume by more than 50% on all but two examinations when the 2-D volume was compared with the 3-D volume. In 28% of follow-up examinations, the 2-D calculation of percent change differed by more than 10% from the 3-D volume. Fifteen percent differed by over 25%. This changed the response category of one patient from “no response” to “partial response”. 3-D volumetric analysis, easily performed by a trained technologist, will give more accurate assessment of the actual tumor bulk and its subsequent changes in size in response to therapy.
An additional, unexpected benefit of volumetric determination and its accompanying 3-D images was their use and enthusiastic acceptance by clinicians. Pediatric oncologists and surgeons used the sequential images in conferences with parents. In the future, graphic representations of tumor response to therapy might be used in determining the best time for second-look surgery or for other therapeutic manipulations.
KeywordsPercent Change Tumor Response Response Category Therapeutic Decision Subsequent Change
Unable to display preview. Download preview PDF.
- 3.Hopper KD, Kasales CJ, Eggli KD, Potok PS et al (1993) 2-D versus 3-D quantitation of tumor response to treatment. Poster, RSNA Annual Meeting, Chicago, Ill, 28 Nov–3 Dec 1993Google Scholar
- 4.Lukens JN, Matthay KK et al (1989) Biology and therapy for good, intermediate and selected poor prognosis neuroblastoma. Children's Cancer Group Protocol 3881, sect. 9.0, response criteria, p26, June 5, 1989Google Scholar
- 5.Matthay KK, Lukens JN, Harris R et al (1991) Conventional dose chemoradiotherapy vs. ablative chemoradiotherapy with autologous bone marrow transplantation for high risk neuroblastoma. Children's Cancer Group Protocol 3891, Sect. 15.0, p 57, Jan 1, 1991Google Scholar
- 6.Hopper K, Kasales CJ, TenHave TR, Potok PS et al (1993) Comparison of phantom volume. RSNA Annual Meeting, Chicago, Ill, 28 Nov–3 Dec 1993Google Scholar